Academics, Allergists, Caregivers, Clinical Pharmacologists, Clinicians, Educators, Formulary Managers, Geriatricians, Gerontologists, HyperTension Specialists, Industrial Scientists, Oncologists, Patients, Pharmaco-Epidemiologists, Pharmacologists, Physiologists, Public Health Professionals, Pulmonologists, Researchers, Residents
"Pulmonary Therapy is an international, open access, peer-reviewed, rapid-publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of pulmonary therapies. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, as well as patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, and short communications. The journal appeals to a global audience and receives submissions from all over the world.